Department of General Surgery, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, People's Republic of China.
Obes Surg. 2012 Oct;22(10):1562-7. doi: 10.1007/s11695-012-0694-0.
Roux-en-Y gastric bypass (RGB) has been endorsed by the "First World Congress on International Therapies for Type 2 diabetes" as a possible therapeutic option in patients with type 2 diabetes with a body mass index (BMI) of less than 35 kg/m(2). In the present study, we assessed the improvement in clinical indicators associated with laparoscopic Roux-en-Y gastric bypass (LRYGB) in patients with non-obese type 2 diabetes mellitus (T2DM).
LRYGB was performed in 30 T2DM patients with a BMI <35 kg/m(2). The patients were followed up for 1 year. Pre- and postoperative changes in BMI, waist circumference, and biochemical indicators including fasting plasma glucose and glycosylated hemoglobin were recorded.
Significant reduction in glycosylated hemoglobin from 8.02 ± 1.77 to 5.59 ± 1.02 % (p < 0.05) at 12 months was noted. Diabetes was completely resolved in nine cases, resulting in discontinuation of diabetes-related medication. No significant surgical complications occurred.
LRYGB is beneficial for non-obese T2DM patients in China.
Roux-en-Y 胃旁路术（RGB）已被“第一届世界 2 型糖尿病国际治疗大会”认可为 BMI 低于 35kg/m²的 2 型糖尿病患者的一种可能的治疗选择。在本研究中，我们评估了腹腔镜 Roux-en-Y 胃旁路术（LRYGB）对非肥胖 2 型糖尿病（T2DM）患者相关临床指标的改善作用。
对 30 例 BMI<35kg/m²的 T2DM 患者进行 LRYGB。对患者进行了为期 1 年的随访。记录 BMI、腰围和空腹血糖、糖化血红蛋白等生化指标的术前和术后变化。
术后 12 个月，糖化血红蛋白从 8.02±1.77%显著降至 5.59±1.02%（p<0.05）。9 例患者糖尿病完全缓解，停止使用糖尿病相关药物。无明显手术并发症发生。
LRYGB 对中国非肥胖 T2DM 患者有益。
